The commentary responds to a short communication by Hamm and colleagues describing computed tomography-guided percutaneous marking of lung nodules using two well-established agents: patent blue V, a visible dye, and indocyanine green, a fluorescent tracer that glows under near-infrared light. The German team also explored indocyanine green-soaked coils, small metallic spirals drenched in the fluorescent dye before deployment. In their reported series, all patients underwent complete resection without conversion to open surgery, a result the commentary authors describe as underscoring the technical reliability of the approach. What makes the technique attractive, they note, is its accessibility and workflow flexibility: the marking is performed percutaneously in the radiology suite, avoiding rigid transpleural devices that must stay in place until resection, and eliminating the need for intraoperative fluoroscopy altogether.

That last point matters more than it might first appear. Robotic-assisted thoracic surgery has transformed minimally invasive lung resection, offering articulated instruments, high-definition three-dimensional vision, and steady precision within a confined chest cavity. But robotic operating environments are notoriously unfriendly to techniques that require a fluoroscope to be wheeled in mid-operation. Hybrid operating rooms equipped with integrated imaging remain scarce and expensive, particularly outside major academic centres. A localisation strategy that relies on preoperative computed tomography guidance and then hands off to near-infrared fluorescence, which integrates seamlessly into robotic camera platforms, preserves operative ergonomics and could allow hospitals without hybrid theatres to offer minimally invasive sublobar resection to their patients. In this sense, the commentary frames computed tomography-guided fluorescence as a platform technology reinforcing the expanding role of interventional radiology in precision thoracic oncology.

To understand where the field is heading, the authors propose a generational framework for pulmonary localisation strategies. The first generation was hook-wire localisation, in which a thin wire with a hooked tip is placed into or adjacent to the nodule under imaging guidance. Wires are effective but carry well-known drawbacks: they can displace, they puncture the pleura and can cause pneumothorax, and the rigid external component must be managed carefully until the surgeon removes it. The second generation was percutaneous dye injection, simple and cheap, but vulnerable to two failure modes: dyes diffuse through the soft lung parenchyma and they fade over time, so the target zone a surgeon sees may no longer correspond to where the dye was originally placed. The third generation introduced coil-assisted fluorescence, in which a metallic coil provides mechanical containment for the fluorescent dye, improving durability and visibility.

It is the fourth generation, still emerging, that excites the commentary’s authors most: stabilised fluorescent matrices designed to optimise spatial fidelity. The central insight is that diffusion control is not a minor technical detail but the very heart of localisation accuracy. When liquid dye is injected into lung tissue, it spreads laterally through the interstitium, creating a fluorescent zone that grows and blurs over time. Visibility without spatial fidelity, the authors warn, risks misleading surgical guidance. In a lobectomy, where the entire lobe is removed, a few millimetres of dye drift are inconsequential. But in a sublobar resection, a segmentectomy or wedge resection intended to preserve as much healthy lung as possible, margin geometry is everything. If the fluorescent cloud has migrated, the surgeon may resect around the wrong centre, compromising the distance between the tumour edge and the cut margin.

The stakes of margin integrity have been raised sharply by randomised evidence. The Japanese JCOG0802/WJOG4607L trial, a multicentre phase 3 study published in The Lancet in 2022, demonstrated that segmentectomy is non-inferior to lobectomy for small peripheral non-small-cell lung cancer, validating lung-preserving surgery for selected early-stage patients. That victory for tissue-sparing oncology, however, makes the localisation problem more acute rather than less. When the goal shifts from removing an entire lobe to carving out a precise wedge around a ten-millimetre lesion, the surgeon depends absolutely on the fidelity of whatever marker was placed the day before. Margin distance and local recurrence become the decisive metrics, and any localisation technique that cannot guarantee spatial accuracy becomes the weak link in an otherwise elegant chain.

This is why the commentary insists that future localisation research be framed by oncologic endpoints rather than technical success alone. Viana and Nunes call for systematic reporting of lesion depth, minimal margin distance, and longitudinal local recurrence in every study of nodule marking. Complete resection rates, while reassuring, are a blunt instrument; a resection can be complete yet carry a margin so narrow that recurrence risk rises. They also urge multicentre prospective validation within robotic workflows, recognising that single-centre feasibility studies, however encouraging, cannot establish whether a technique performs consistently across different operators, scanner platforms, and patient anatomies. Whether molecular stabilisation of fluorescent dyes translates into superior oncologic precision, they acknowledge, requires exactly this kind of prospective evaluation, but the conceptual evolution is notable.

The stabilised matrix concept represents a genuinely biochemical approach to a problem that previous generations attacked mechanically. Rather than containing dye with a coil or accepting its diffusion as inevitable, these formulations modulate dye distribution at the injection site itself, reducing lateral spread and potentially improving margin predictability. The commentary’s authors have direct experience in this territory: they previously published a technical note on computed tomography-guided dual-fluorescent marking for robotic sublobar resection covering 84 consecutive cases, work cited in their commentary as part of the field’s progression. Their argument is that these four generations, hook-wires, dye injections, coil-assisted fluorescence, and stabilised matrices, should be understood not as competitors but as iterative refinements, each responding to a clearly identified limitation of its predecessor.

For readers wondering why this seemingly niche surgical debate deserves broader attention, the answer lies in the convergence of three trends that are reshaping cancer care worldwide. Screening programmes are expanding, which means more small nodules will be found and more of them will be operated on. Robotic platforms are proliferating, which means more of those operations will be performed with instruments that cannot palpate a lesion hidden in deflated lung tissue. And lung-preserving resection is gaining evidence-based legitimacy, which means the precision demands on localisation will only intensify. The commentary’s closing line captures the moment succinctly: if feasibility has defined the past decade of computed tomography-guided localisation, precision will define the next. What began as a practical question of how to mark a spot in the lung is maturing into a rigorous discipline of spatial oncology, where the biochemistry of a dye, the geometry of a surgical margin, and the long-term risk of cancer recurrence are inseparably linked.

There are, of course, caveats that the commentary itself makes explicit. The heterogeneity of marking techniques currently in use, spanning simple dye injection and coil-assisted fluorescence, reflects an important developmental phase but may limit standardisation, making head-to-head comparisons difficult. The stabilised fluorescent matrices remain conceptually promising rather than prospectively proven, and their advantage over coil containment must be demonstrated in controlled studies. Nor does the commentary claim that any single technique is universally superior; instead, it offers a roadmap for how the field should evaluate its options. For a specialty in which a few millimetres of tissue can determine whether a patient keeps half a lung or loses a whole one, that shift in standards, from visible to verifiable, from feasible to faithful, may prove to be the most consequential development in thoracic surgical oncology this decade.

Subject of Research: Computed tomography-guided fluorescent localisation of small pulmonary nodules for robotic thoracic surgery

Article Title: Evolving generations of computed tomography-guided lung nodule localisation toward stabilised fluorescent precision in robotic thoracic oncology

Article References: Viana, P. C. C., & Nunes, T. F. (2026). Evolving generations of computed tomography-guided lung nodule localisation toward stabilised fluorescent precision in robotic thoracic oncology. CVIR Oncology, 2(1), Article 31. https://doi.org/10.1007/s44343-026-00036-4

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00036-4

Keywords: lung nodule localisation, computed tomography guidance, indocyanine green, patent blue V, fluorescence imaging, robotic thoracic surgery, sublobar resection, segmentectomy, surgical margins, interventional radiology, precision oncology, stabilised fluorescent matrices